Skip to main content
. 2024 Oct 31;17(11):1459. doi: 10.3390/ph17111459

Figure 2.

Figure 2

Current evidence-based approach to choice of oral anticoagulation in patients with AF with underlying VHD. The left panel depicts the subset of VHD, while the middle panel suggests the appropriate oral anticoagulant—DOAC/VKA. The right panel displays the evidence base for recommendation of oral anticoagulant in each scenario. [VHD, valvular heart disease; TAVR—transcatheter aortic valve replacement; MS—mitral stenosis; DOAC, direct oral anticoagulant; VKA—Vitamin K antagonist].